Xiong Anji, Luo Wenxuan, Tang Xiaoyu, Cao Yuzi, Xiang Qilang, Deng Ruiting, Shuai Shiquan
Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College, Nanchong, Sichuan, China; Inflammation and Immunology Key Laboratory of Nanchong, Nanchong, China.
Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
Semin Arthritis Rheum. 2023 Dec;63:152257. doi: 10.1016/j.semarthrit.2023.152257. Epub 2023 Aug 22.
Invasive fungal infections (IFIs) are life-threatening opportunistic infections in patients with connective tissue disease CTD) that cause significant morbidity and mortality. We attempted to determine the potential risk factors associated with IFIs in CTD.
We systematically searched PubMed, Embase, and the Cochrane Library databases for relevant articles published from the database inception to February 1, 2023.
Twenty-six studies were included in this systematic review and meta-analysis. Risk factors identified for IFIs were diabetes (odds ratio [OR], 1.62; 95% confidence interval [CI], 1.00 to 2.64), pulmonary diseases (OR 3.43; 95% CI 2.49 to 4.73), interstitial lung disease (ILD; OR, 4.06; 95% CI, 2.22 to 7.41), renal disease (OR, 4.41; 95% CI, 1.84 to 10.59), glucocorticoid (GC) use (OR, 4.15; 95% CI, 2.74 to 6.28), especially moderate to high-dose GC, azathioprine (AZA) use (OR, 1.50; 95% CI, 1.12 to 2.01), calcineurin inhibitor (CNI) use (OR, 2.49; 95% CI, 1.59 to 3.91), mycophenolate mofetil (MMF) use (OR, 2.83; 95% CI, 1.59 to 5.03), cyclophosphamide (CYC) use (OR, 3.35; 95% CI, 2.47 to 4.54), biologics use (OR, 3.43; 95% CI, 2.36 to 4.98), and lymphopenia (OR, 4.26; 95% CI, 2.08 to 8.73). Hydroxychloroquine (HCQ) use reduced risk of IFIs (OR, 0.67; 95% CI, 0.54 to 0.84). Furthermore, 17 of the 26 studies only reported risk factors for Pneumocystis jiroveci pneumonia (PJP) in patients with CTD. Pulmonary disease; ILD; and the use of GC, CNIs, CYC, methotrexate (MTX), MMF and biologics, and lymphopenia increased the risk of PJP, whereas the use of HCQ reduced its risk.
Diabetes, pulmonary disease, ILD, renal disease, use of GC (especially at moderate to high dose) and immunosuppressive drugs, and lymphopenia were found to be associated with significant risk for IFIs (especially PJP) in patients with CTD. Furthermore, the use of HCQ may reduce the risk of IFIs in patients with CTD.
侵袭性真菌感染(IFI)是结缔组织病(CTD)患者中危及生命的机会性感染,会导致显著的发病率和死亡率。我们试图确定与CTD患者IFI相关的潜在风险因素。
我们系统检索了PubMed、Embase和Cochrane图书馆数据库,以查找从数据库建立至2023年2月1日发表的相关文章。
本系统评价和荟萃分析纳入了26项研究。确定的IFI风险因素包括糖尿病(比值比[OR],1.62;95%置信区间[CI],1.00至2.64)、肺部疾病(OR 3.43;95% CI 2.49至4.73)、间质性肺疾病(ILD;OR,4.06;95% CI,2.22至7.41)、肾脏疾病(OR,4.41;95% CI,1.84至10.59)、使用糖皮质激素(GC)(OR,4.15;95% CI,2.74至6.28),尤其是中高剂量GC、使用硫唑嘌呤(AZA)(OR,1.50;95% CI,1.12至2.01)、使用钙调神经磷酸酶抑制剂(CNI)(OR,2.49;95% CI,1.59至3.91)、使用霉酚酸酯(MMF)(OR,2.83;95% CI,1.59至5.03)、使用环磷酰胺(CYC)(OR,3.35;95% CI,2.47至4.54)、使用生物制剂(OR,3.43;95% CI,2.36至4.98)以及淋巴细胞减少(OR,4.26;95% CI,2.08至8.73)。使用羟氯喹(HCQ)可降低IFI风险(OR,0.67;95% CI,0.54至0.84)。此外,26项研究中的17项仅报告了CTD患者中耶氏肺孢子菌肺炎(PJP)的风险因素。肺部疾病、ILD以及使用GC、CNIs、CYC、甲氨蝶呤(MTX)、MMF和生物制剂以及淋巴细胞减少会增加PJP风险,而使用HCQ可降低其风险。
发现糖尿病、肺部疾病、ILD、肾脏疾病、使用GC(尤其是中高剂量)和免疫抑制药物以及淋巴细胞减少与CTD患者发生IFI(尤其是PJP)的显著风险相关。此外,使用HCQ可能会降低CTD患者发生IFI的风险。